Report cover image

VAP-1 Inhibitors - Pipeline Insight, 2025

Publisher DelveInsight
Published Apr 01, 2025
Length 60 Pages
SKU # DEL19993580

Description

DelveInsight’s, “VAP-1 Inhibitors- Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs based on VAP-1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
VAP-1 Inhibitors Understanding

VAP-1 Inhibitors: Overview

Vascular adhesion protein-1 (VAP-1) is an ectoenzyme that oxidates primary amines in a reaction producing also hydrogen peroxide. VAP-1 on the blood vessel endothelium regulates leukocyte extravasation from the blood into tissues under physiological and pathological conditions. Inhibition of VAP-1, also known as AOC3 protein inhibitors by neutralizing antibodies and by several novel small-molecule enzyme inhibitors interferes with leukocyte trafficking and alleviates inflammation in many experimental models. Targeting of VAP-1 also shows beneficial effects in several other diseases, such as ischemia/reperfusion, fibrosis, and cancer. Moreover, soluble VAP-1 levels may serve as a new prognostic biomarker in selected diseases.

VAP-1 Inhibitors Emerging Drugs Chapters

This segment of the VAP-1 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

VAP-1 Inhibitors Emerging Drugs
  • TERN-201: Terns Pharmaceuticals
TERN-201 is a potent SSAO inhibitor which provides an additional treatment mechanism for NASH by reducing oxidative stress and recruitment of white blood cells to the liver. TERN-201 is highly specific for SSAO, with a preferential in vitro selectivity index to SSAO over off-target monoamine oxidases (MAO) of >7,000-fold. Certain MAOs could be associated with potential drug-drug interactions in the NASH patient population. It is in phase I stage of development.
  • PRX 167700: Proximagen
PRX167700 is a vascular adhesion protein-1 (VAP-1; AOC3) antagonist that is being developed by Proximagen (a subsidiary of BenevolentAI) for the treatment for Inflammatory pain. It is currently in phase II stage of development.
  • TT-01025: TransThera Biosciences
TT-01025 is a novel inhibitor of Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) for NASH. LG Chem Life Sciences and TransThera Biosciences jointly announced the Investigational New Drug (IND) application of TT-01025 has been submitted to Food and Drug Administration (FDA) in the United States.

Further product details are provided in the report……..

VAP-1 Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different VAP-1 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in VAP-1 Inhibitors
There are approx. 15+ key companies which are developing the therapies based on VAP-1 Inhibitors. The companies which have their drug candidate based on VAP-1 Inhibitors in the most advanced stage, i.e. phase II include Proximagen and others
  • Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage products (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
VAP-1 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Gene therapies
  • Small molecule
  • Vaccines
  • Polymers
  • Peptides
  • Monoclonal antibodies
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

VAP-1 Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses VAP-1 Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging VAP-1 Inhibitors drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence VAP-1 Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • In September 2020, Terns Pharmaceuticals announced that TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of non-alcoholic steatohepatitis (NASH).
  • LG Chem reached an exclusive license agreement with TransThera Biosciences on August 2020 to research, develop, manufacture and commercialize TT-01025 in global region except Greater China and Japan.
VAP-1 Inhibitors Report Insights
  • VAP-1 Inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
VAP-1 Inhibitors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions
  • What are the current treatment options available based on the VAP-1 Inhibitors?
  • How many companies are developing therapies by working on VAP-1 Inhibitors?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for VAP-1 Inhibitors to treat disease condition?
  • How many emerging therapies are in early-stage, mid-stage, and late stage of development for VAP-1 Inhibitors?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the VAP-1 Inhibitors therapies?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies developed based on this mechanism of action?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for VAP-1 Inhibitors and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for VAP-1 Inhibitors?
  • How many patents are granted and pending for the emerging therapies of VAP-1 Inhibitors?
Key Players
  • Terns Pharmaceuticals
  • Proximagen
  • TransThera Biosciences
  • Pharmaxis
  • Acorda Therapeutics
  • R-Tech Ueno
  • Pharmaxis
Key Products
  • TT-01025
  • PRX 167700
  • TERN-201
  • Research programme: SSAO/VAP-1 protein inhibitors
  • Research programme: VAP-1 SSAO enzyme inhibitors
  • RTU 1096
  • BI 1467335

Table of Contents

60 Pages
Introduction
Executive Summary
VAP-1 Inhibitors: Overview
Structure
Mechanism of Action
Classification
Application
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
VAP-1 Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
VAP-1 Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
VAP-1 Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
PRX 167700: Proximagen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TERN-201: Terns Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
TT-01025: TransThera Biosciences
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
VAP-1 Inhibitors Key Companies
VAP-1 Inhibitors Key Products
VAP-1 Inhibitors- Unmet Needs
VAP-1 Inhibitors- Market Drivers and Barriers
VAP-1 Inhibitors- Future Perspectives and Conclusion
VAP-1 Inhibitors Analyst Views
VAP-1 Inhibitors Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us